• No disease-modifying medications for the treatment of Alzheimer disease have been
approved in Canada.• Lecanemab was the first disease-modifying medication for Alzheimer …

Alzheimer's disease (AD) is a neurodegenerative disorder that accounts for 60%–70% of
patients with dementia, and it is estimated that over one million Canadians will be living with …

Currently, there are two medications approved by the Food and Drug Administration (FDA)
for the treatment of Alzheimer's disease (AD). Tacrine (Cognex) was the first, approved in …

Purpose Alzheimer disease (AD) is a growing global health and economic issue as elderly
populations increase dramatically across the world. Despite the many clinical trials …

on the implications of APOE status. The determination of the APOE status is important given
the higher risk of ARIA in E4 carriers, specifically in homozygotes in the case of Lecanemab …

Alzheimer disease (AD) is an insidious, progressive and irreversible brain disorder. Its
incidence is highest in people aged over 65, a cohort forecast to grow by 62% between …

PERSPECTIVE n engl j med 368; 13 nejm. org march 28, 2013 1170 the progression of
disease, at a stage when neuronal damage had become too widespread. According to some …

Alzheimer disease (AD), the most common form of dementia, affects more than 5 million US
residents and progressively leads to a loss of memory and cognitive function. 1 The advent …

In 2021, the US Food and Drug Administration (FDA) granted approval to aducanumab, an
antiamyloid antibody for early-stage Alzheimer's disease, despite a lack of clear clinical …

BACKGROUND: Eighteen-month-long randomized, placebo-controlled clinical trials are
common for phase II and phase III drug development for Alzheimer's disease (AD). Yet, no …